Advertisement

Treatment of Cardiac Allograft Rejection

  • LW. Miller

Abstract

The development of the endomyocardial biopsy by Caves et al.[1] was one of the most important developments in the management of heart transplant recipients, and remains the gold standard today for the diagnosis of allograft rejection. Subsequent investigation has shown that a minimum of four and preferably five adequate pieces of endomyocardium are required to achieve satisfactory diagnostic accuracy[2]. The samples should be taken from as many different locations as possible for maximum sensitivity, a task perhaps made easier by use of echocardiography (versus fluoroscopy) to guide the bioptome and allow safe sampling from the anterior free wall and apex[3]–[3].

Keywords

Acute Rejection Heart Transplant Allograft Rejection Mycophenolate Mofetil Heart Transplant Recipient 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Caves P, Billingham M, Slinson E et al. Serial transvenous biopsy of the transplanted human heart. Improved management of acute rejection episodes. Lancet. 1974;1:821.PubMedCrossRefGoogle Scholar
  2. 2.
    Zerbe T, Arena V. Diagnostic reliability of endomyocardial biopsy for assessment of cardiac allograft rejection. Hum Pathol. 1988;19:1307.PubMedCrossRefGoogle Scholar
  3. 3.
    Miller L, Labovitz A, McBride L et al. Echocardiography-guided endomyocardial biopsy: a 5-year experience. Circulation. 1988;78(Suppl.III)14–99.Google Scholar
  4. 4.
    O’Connell JB, Renlund DG. Variations in the diagnosis, treatment and prevention of cardiac allografl rejection: the need for standardization? J Heart Transplant. 1990;9:269.PubMedGoogle Scholar
  5. 5.
    Lloveras J, Escourrou G, DeLisle M et al. Evolution of untreated mild rejection in heart transplant recipients. J Heart Lung Transplant. 1992;11:751.PubMedGoogle Scholar
  6. 6.
    Winters GL, Loh E, Schoen FJ. Natural history of focal moderate cardiac allograft rejection. Is treatment warranted? Circulation. 1995;91:1975.PubMedGoogle Scholar
  7. 7.
    Fishbein M, Bell G, Lones M et al. Grade 2 cellular heart rejection: does it exist? J Heart Lung Transplant. 1994;13:1051.PubMedGoogle Scholar
  8. 8.
    Yeoh T, Frist W, Eastburn T et al. Clinical significance of mild rejection of the cardiac allograft. Circulation. 1992;86:11–267.Google Scholar
  9. 9.
    Basadonna. G, Matas A, Gillingham K et al. Early versus late acute renal allograft rejection: impact on chronic rejection. Transplantation. 1993:55:993.PubMedCrossRefGoogle Scholar
  10. 10.
    Almond P, Matas A, Gillingham K et al. Risk factors for chronic rejection in renal allograft recipients. Transplantation. 1993;55:752.PubMedCrossRefGoogle Scholar
  11. 11.
    Costanzo-Nordin M. Cardiac allograft vasculopathy: relationship with acute cellular rejection and hislocompatibility. J Heart Lung Transplant. 1992;11:S90.PubMedGoogle Scholar
  12. 12.
    Gao S, Schroeder J, Hunt S et al. Influence of graft rejection on incidence of accelerated graft coronary artery disease: a new approach to analysis. J Heart Lung Transplant. 1993;12:1029.PubMedGoogle Scholar
  13. 13.
    Slovin P, Sharpies L, Schofield P et al. Lack of association between endomyocardial evidence of rejection in the first six months and the later development of transplantrelated coronary artery disease. J Heart Lung Transplant. 1993;12:110.Google Scholar
  14. 14.
    Kobashigawa J, Sandoz/CVIS Investigators. Does acute rejection correlate with the development of transplant coronary artery disease? A multi-center study using intravascular ultrasound. J Heart Lung Transplant. 1995;14:5221–6.Google Scholar
  15. 15.
    Anguita M, Lopez-Rubio F, Arizon J et al. Repetitive nontreated episodes of grade 1B or 2 acute rejection impair long-term cardiac graft function. J Heart Lung Transplant. 1995;14:452.PubMedGoogle Scholar
  16. 16.
    Kubo S, Naftel D, Mills R et al. Risk factors for late recurrent rejection after heart transplantation: a multiinstitutional, multivariable analysis. J Heart Lung Transplant. 1995;14:409.PubMedGoogle Scholar
  17. 17.
    Kobashigawa J Kirklin J, Naftel D et al. Pretransplantation risk factors for acute rejection after heart transplantation: a multi-institutional study. J Heart Lung Transplant. 1993;12:355.PubMedGoogle Scholar
  18. 18.
    Jarcho J, Naftel D, Shroyer T et al. Influence of HLA mismatch on rejection after heart transplantation: a multiinstitutional study. J Heart Lung Transplant. 1994;13:583.PubMedGoogle Scholar
  19. 19.
    Rizeq M, Masek M, Billingham M. Acute rejection: significance of elapsed time post-transplant. J Heart Lung Transplant. 1994;13:862.PubMedGoogle Scholar
  20. 20.
    Costanzo-Nordin MC, Heroux AL, Radvany R et al. Role of humoral immunity in acute cardiac allograft dysfunction. J Heart Lung Transplant. 1993;12:SI43.Google Scholar
  21. 21.
    Ensley RD, Hammond EH, Renlund DG et al. Clinical manifestations of vascular rejection in cardiac transplantation. Transplant Proc. 1991;23:1130.PubMedGoogle Scholar
  22. 22.
    Oyer P, Stinson E, Biebcr C et al. Diagnosis and treatment of acute cardiac allograft rejection. Transplant Proc. 1979;11:296.PubMedGoogle Scholar
  23. 23.
    Heublein B, Wahlers T, Haverich A. Pulsed steroids for treatment of cardiac rejection after transplantation. What dosage is necessary? Circulation. 1989;80(5:2):III–97–9.Google Scholar
  24. 24.
    Miska. P, Bates L, Collins C et al. Methylprednisolone pulsing of heart transplant patients in the home. J Heart Transplant. 1988;7:353.PubMedGoogle Scholar
  25. 25.
    Smith R, Warren D. Effects of high-dose intravenous methylprednisolone on circulation in humans. Transplantation. 1983;35:349.PubMedCrossRefGoogle Scholar
  26. 26.
    Kobashigawa JA, Stevenson LW, Moriguchi JD et al. Is intravenous glucocorticoid therapy better than an oral regimen for asymptomatic cardiac rejection? A randomized trial. J Am Coll Cardiol. 1993;21:1142.PubMedGoogle Scholar
  27. 27.
    Michler R, Smith C, Drusin R et al. Reversal of cardiac transplant rejection without massive immunosuppression. Circulation. 1986;74(Suppl.III):III–68.Google Scholar
  28. 28.
    Lonquist J, Radovancevic B, Vega J et al. Reevaluation of steriod tapering after steroid pulse therapy for heart rejection. J Heart Lung Transplant. 1992;11:913.PubMedGoogle Scholar
  29. 29.
    Miller LW. Treatment of cardiac allograft rejection with intravenous corticosteriods. J Heart Transplant. 1990;9:283.PubMedGoogle Scholar
  30. 30.
    Gilbert E, DeWitt C, Eiswirth C et al. Treatment of refractory cardiac allograft rejection with OKT3 monoclonal antibody. Am J Med. 1987;82:202.PubMedCrossRefGoogle Scholar
  31. 31.
    Mason JW, Stinson EB, Hunt SA et al. Infections after cardiac transplantation: relation to rejection therapy. Ann Intern Med. 1976;85:69.PubMedGoogle Scholar
  32. 32.
    Macris M, Frazier O, Van Buren C et al. Improved immunosuppression for heart transplant patients using intravenous doses of cyclosporin. Transplantation. 1989;47:311.PubMedCrossRefGoogle Scholar
  33. 33.
    Kobashigawa J, Stevenson L, Moriguchi J et al. Randomized study of high-dose oral cyclosporin therapy for mild acute cardiac rejection. J Heart Lung Transplant. 1989;8:53.Google Scholar
  34. 34.
    Radovancevic B, Frazier O. Treatment of moderate heart allograft rejection with cyclosporin. J Heart Lung Transplant. 1986;5:307.Google Scholar
  35. 35.
    Steinmuller DR. FK506 and organ transplantation. R.G. Landes Co., Molecular Biology Intelligence Unit, Boca Raton; CRC Press: 1994.Google Scholar
  36. 36.
    Armitage J, Kormos R, Morita S et al. Clinical trial of FK506 immunosuppression in adult cardiac transplantation. Ann Thorac Surg. 1992;54:2O5.Google Scholar
  37. 37.
    Costanzo-Nordin M, Grusk B, Silver M et al. Reversal of recalcitrant cardiac allograft rejection with methotrexate. Circulation. 1988;78:III 47.Google Scholar
  38. 38.
    Boucharl F, Gundry S, Van Schaack-Gonzales J et al. Methotrexale as rescue/ adjunctive immunotherapy in infant and adult heart transplantation. J Heart Lung Transplant. 1993;12:427.Google Scholar
  39. 39.
    Bourge R, Kirklin J, White-Williams C et al. Methotrexate pulse therapy in the treatment of recurrent acute heart rejection. J Heart Lung Transplant. 1992;11:1116.PubMedGoogle Scholar
  40. 40.
    Olsen S, O’Connell J, Bristow M et al. Methotrexate as an adjunct in the treatment of persistent mild cardiac allograft rejection. Transplantation. 1990;50:773.PubMedCrossRefGoogle Scholar
  41. 41.
    Hosenpud J, Hershberger R, Ratkovec R et al. Methotrexate for the treatment of patients with multiple episodes of acute cardiac allograft rejection. J Heart Lung Transplant. 1992;11:739.PubMedGoogle Scholar
  42. 42.
    Costanzo M, Koch D, Fisher S et al. Effect of methotrexate on acute rejection in allograft vasculopathy in heart transplant recipients. J Heart Lung Transplant (in press).Google Scholar
  43. 43.
    Shaddy R, Bullock E, Tani L et al. Methotrexate therapy in pediatric heart transplantation as treatment of recurrent mild to moderate acute rejection. J Heart Lung Transplant. 1994;13:1009.PubMedGoogle Scholar
  44. 44.
    Jennison S, Wesp A, Wolford T et al. The use of chronic maintenance metholrexate therapy in cardiac transplant recipients. Presented to the American Society of Transplant Physicians, Chicago, IL, 1993.Google Scholar
  45. 45.
    Kirklin J, Bourge R, Naftel D et al. Treatment of recurrent heart rejection with mycophenolate mofetil (RS-61443): initial clinical experience. J Heart Lung Transplant. 1994;13:444.PubMedGoogle Scholar
  46. 46.
    Taylor D, Ensley R, Olsen S et al. Mycophenolate mofetil (RS-61443): preclinical, clinical and three year experience in heart transplantation. J Heart Lung Transplant. 1994;13:S71.Google Scholar
  47. 47.
    Salter M, Kirklin J, Bourge R et al. Total lymphoid irradiation in the treatment of early or recurrent heart rejection. J Heart Lung Transplant. 1992;11:902.PubMedGoogle Scholar
  48. 48.
    Evans MA, Schoimberg PJ, Rodeheffer RJ et al. Total lymphoid irradiation: a novel and successful therapy for resistant cardiac allograft rejection. Mayo Clinic Proc. 1992;67:785.Google Scholar
  49. 49.
    Hunt S, Strober S, Hoppe RT et al. Total lymphoid irradiation for treatment of intractable cardiac allograft rejection. J Heart Lung Transplant. 1991;10:211.PubMedGoogle Scholar
  50. 50.
    Kirklin JK, George JF, McGiftin DC et al. Total lymphoid irradiation: is there a role in pediatric heart transplantation? J Heart Lung Transplant. 1993;I2:S923.Google Scholar
  51. 51.
    Costanzo-Nordin M, Hubbell E, O’Sullivan J et al. Photopheresis versus corticosteroids in the therapy of heart transplant rejection. Preliminary clinical report. Circulation. 1992;86:11242.Google Scholar
  52. 52.
    Costanzo-Nordin MC, Hubbell EA, O’Sullivan EJ et al. Successful treatment of heart transplant with photopheresis. Transplantation. 1992;53:808.PubMedCrossRefGoogle Scholar
  53. 53.
    Rose E, Barr M, Xu H et al. Photochemotherapy in human heart transplant recipients at high risk for fatal rejection. J Heart Lung Transplant. 1992;11:746.PubMedGoogle Scholar
  54. 54.
    Meiser BM, Kur F, Reichenspurner H et al. Reduction of the incidence of rejection by adjunct immunosuppression with photochemotherapy after heart transplantation. Transplantation. 1994;57:463.CrossRefGoogle Scholar
  55. 55.
    Sweeney M, Macris M, Frazier O et al. The treatment of advanced cardiac allograft rejection. Ann Thorac Surg. 1988;46:378.PubMedCrossRefGoogle Scholar
  56. 56.
    Frist W, Gerhardt E, Merrill W et al. Therapy of refractory, recurrent heart rejection with multiple courses of OKT3. J Heart Transplant. 1990;9:724.PubMedGoogle Scholar
  57. 57.
    O’Connell J, Renlund G, Day W et al. Efficacy of OKT3 retreatment for refractory cardiac allograft rejection. Transplantation. 1989;47:788.PubMedGoogle Scholar
  58. 58.
    Haverty TP, Sanders M, Sheahan M. OKT3 treatment of cardiac allograft rejection. J Heart Lung Transplant. 1993;12:591.PubMedGoogle Scholar
  59. 59.
    Bristow M, Gilbert E, Renlund D et al. Use of 0KT3 monoclonal antibody in heart transplantation: review of the initial experience. J Heart Lung Transplant. 1988;7:1.Google Scholar
  60. 60.
    Norman DJ, Kimball JA, Bennett WM et al. A prospective, double-blind, randomized study of high-versus low-dose OKT3 induction immunosuppression in cadaveric renal transplantation. Transpl Int. 1994;7:356.PubMedCrossRefGoogle Scholar
  61. 61.
    Hammond E, Wittwer C, Greenwood J et al. Relationship of OKT3 sensitization and vascular rejection in cardiac transplant patients receiving OKT3 rejection prophylaxis. Transplantation. 1990;50:776.PubMedCrossRefGoogle Scholar
  62. 62.
    Ellenhorn J, Woodle E, Ghobreal I et al. Activation of human T cells in vivo following treatment of transplant recipients with OKT3. Transplantation. 1990;50:608.PubMedCrossRefGoogle Scholar
  63. 63.
    Chatenoud L, Ferran C, Reuter A et al. Systemic reaction to the anti-T cell monoclonal antibody OKT3 in relation to serum levels of tumor necrosis factor and interferon gamma. N Engl J Med. 1989;320:1420.PubMedGoogle Scholar
  64. 64.
    Chatenoud L, Ferran C, Legendre C et al. In vivo cell activation following OKT3 administration: systemic cytokine release and modulation by corticosteroids. Transplantation. 1990;49:697.PubMedCrossRefGoogle Scholar
  65. 65.
    Hosenpud J, Norman D, Pantely G et al. OKT3 induced hypotension in heart allograft recipients treated for steroid resistant rejection. J Heart Transplant. 1989;8:159.PubMedGoogle Scholar
  66. 66.
    Wagner F, Reichenspumer H, Uberfuhr P et al. How successful is OKT3 rescue therapy for steroid resistant acute rejection episodes after heart transplantation? J Heart Lung Transplant. 1994;13:438.PubMedGoogle Scholar
  67. 67.
    Goldstein G, Fuccello A, Norman D et al. OKT3 monoclonal antibody plasma levels during therapy and the subsequent development of host antibodies to OKT3. Transplantation. 1986;43:507.Google Scholar
  68. 68.
    Spiegel JE, Level AS. Life-threatening thrombocytopenia complicating antithymocyte globulin therapy for acute kidney transplant rejection. Transplantation. 1988;45:647.PubMedCrossRefGoogle Scholar
  69. 69.
    Lebeck LK, Chang L, Lopez-McCormack C et al. Polyclonal antithymocyte serum: immune prophylaxis and rejection therapy in pediatric heart transplantation patients. J Heart Lung Transplant. 1993;12:S286.PubMedGoogle Scholar
  70. 70.
    Adamson R, Dembitsky W, Wormsley S et al. 0KT3 vs ATG: is there really a difference in immunosuppressive potency? Evaluation of rejection and effect on peripheral blood lymphocytes in heart transplant recipients. J Heart Transplant. 1989;8:A74 (abstract).Google Scholar
  71. 71.
    Renlund D, O’Connell J, Gilbert E et al. A prospective comparison of murine monoclonal CD-3 (OKT3) antibody based on equine antithymocyte globulin-based rejection prophylaxis in cardiac transplantation. Transplantation. 1989;47:599.PubMedCrossRefGoogle Scholar
  72. 72.
    Griffith B, Kormos R, Armitage J et al. Comparative trial of immunoprophylaxis with RATG versus OKT3. J Heart Transplant. 1990;9:301.PubMedGoogle Scholar
  73. 73.
    Costanzo-Nordin M, O’Sullivan E, Johnson M et al. Prospective randomized trial of 0KT3 versus horse antithymocyte globulin-based immunosuppressive prophylaxis. J Heart Transplant. 1990;9:306.Google Scholar
  74. 74.
    Hammond EH, Yowell RL, Nunoda S et al. Vascular (humoral) rejection in heart transplantation: pathologic observations and clinical implications. J Heart Transplant. 1989;8:430.PubMedGoogle Scholar
  75. 75.
    Rose ML. Antibody mediated rejection following cardiac transplantation. Transplant Rev. 1993;7:140.CrossRefGoogle Scholar
  76. 76.
    Schuurman H, Jambroes G, Borleffs J et al. Acute humoral rejection in a heart transplant recipient. Transplant Proc. 1989;21:2529.PubMedGoogle Scholar
  77. 77.
    Trento A, Hardesty R, Griffith B et al. Role of the antibody to vascular endothelial cells in hyperacute rejection in patients undergoing cardiac transplantation. J Thorac Cardiovasc Surg. 1988;95:37.PubMedGoogle Scholar
  78. 78.
    Brasile L, Zerbe T, Rabin B et al. Identification of the antibody to vascular endothelial cells in patients undergoing cardiac transplantation. Transplantation. 1985;40:672.PubMedCrossRefGoogle Scholar
  79. 79.
    Olsen S, Wagoner L, Hammond E et al. Vascular rejection in cardiac transplantation: clinical correlation, treatment options and future considerations. J Heart Lung Transplant. 1993;12:S135.PubMedGoogle Scholar
  80. 80.
    Ratkovec R, Hammond EH, O’Connell JB et al. Outcome of cardiac transplant recipients with a positive donor-specific crossmatch-preliminary results with plasmapheresis. Transplantation. 1992;54:641.CrossRefGoogle Scholar
  81. 81.
    Partanen J, Nieminen M, Krogerus L et al. Heart transplant rejection treated with plasmapheresis. J Heart Lung Transplant. 1992;11:301PubMedGoogle Scholar
  82. 82.
    Olivari MT, May CG, Johnson NA et at. Treatment of acute vascular rejection with immunoadsorption. Circulation. 1994,90:11–70.Google Scholar
  83. 83.
    Schroeder T, Weiss M, Smith R et al. The efficacy of OKT3 in vascular rejection. Transplantation. 1991;51:312.PubMedCrossRefGoogle Scholar

Copyright information

© Kluwer Academic Publishers 1996

Authors and Affiliations

  • LW. Miller

There are no affiliations available

Personalised recommendations